Idiopathic Anemia of Aging (IAA)

NCT00104169 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2008-08-29

No results posted yet for this study

Summary

The purpose of this trial is to examine whether Epoetin Alfa, a hormone stimulating production of red blood cells, can reverse idiopathic anemia.

Conditions

Interventions

DRUG

Epoetin Alfa

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    lead NIH

Principal Investigators

  • William Ershler, MD · NIA, NIH

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2007-05-31
Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00104169 on ClinicalTrials.gov